Company intelligence / Profile preview

Century Therapeutics

Philadelphia, Pennsylvania, United Statescenturytx.com ↗

Ownership: Public · IPSC
Employees: ~145
Development stage: Phase 1

Overview

Currently conducting CALiPSO-1 Phase 1 trial for CNTY-101 in autoimmune diseases with first patient scheduled for dosing in March 2025. Recently discontinued ELiPSE-1 trial in late-stage R/R NHL as data did not meet threshold to be considered transformational, though the company remains encouraged by clinical activity and tolerability profile. CARAMEL investigator-initiated trial expected to commence in mid-2025 following CTA approval.[5][9]

Therapeutic areas: OncologyImmunologyRheumatology
Modalities: Allogeneic iPSC-derived NK and T cell therapies
Industry: Biotech

Drug pipeline

22 assets

CNTY-101

21 more assets in the full pipeline.

Request access →

Partnerships

Bristol Myers Squibb (research collaboration and license agreement for iPSC-derived engineered NK and T cell programs)[2]

Financials

Market cap: $175.7M
Total revenue: $0
Enterprise value: $90.6M

Beyond the preview

Go deeper on Century Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Century Therapeutics.

Explore the full profile